MX386895B - Formulaciones oculares para suministro de farmaco al segmento posterior del ojo - Google Patents

Formulaciones oculares para suministro de farmaco al segmento posterior del ojo

Info

Publication number
MX386895B
MX386895B MX2018014122A MX2018014122A MX386895B MX 386895 B MX386895 B MX 386895B MX 2018014122 A MX2018014122 A MX 2018014122A MX 2018014122 A MX2018014122 A MX 2018014122A MX 386895 B MX386895 B MX 386895B
Authority
MX
Mexico
Prior art keywords
eye
posterior segment
drug
delivery
ocular formulations
Prior art date
Application number
MX2018014122A
Other languages
English (en)
Inventor
David P Bingaman
Martin B Wax
Paul G Chaney
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MX386895B publication Critical patent/MX386895B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere con formulaciones tópicas que comprenden un compuesto de la siguiente formula: (ver formula) para tratar la neovascularizacion ocular; el Compuesto I esta presente en una solución o una suspensión en aproximadamente 0.005% a aproximadamente 5.0% p/v, de manera que la solución 15 o suspensión suministre el compuesto al segmento posterior del ojo para inhibir el VEGF en la retina y/o el coroide.
MX2018014122A 2013-03-14 2014-03-14 Formulaciones oculares para suministro de farmaco al segmento posterior del ojo MX386895B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784681P 2013-03-14 2013-03-14
PCT/US2014/027589 WO2014152661A1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye

Publications (1)

Publication Number Publication Date
MX386895B true MX386895B (es) 2025-03-19

Family

ID=50625096

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012653A MX360888B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.
MX2018014122A MX386895B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de farmaco al segmento posterior del ojo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012653A MX360888B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.

Country Status (22)

Country Link
US (8) US10092549B2 (es)
EP (2) EP2968650B1 (es)
JP (3) JP6542193B2 (es)
KR (2) KR102433489B1 (es)
CN (2) CN111789814B (es)
AU (3) AU2014239252B2 (es)
BR (1) BR112015021334B1 (es)
CA (1) CA2900840C (es)
DK (1) DK2968650T3 (es)
ES (1) ES2710152T3 (es)
HU (1) HUE042528T2 (es)
IL (2) IL240510B (es)
MX (2) MX360888B (es)
PH (2) PH12015501938B1 (es)
PL (1) PL2968650T3 (es)
PT (1) PT2968650T (es)
RU (2) RU2665953C2 (es)
SA (1) SA516380321B1 (es)
SG (2) SG10201710928PA (es)
TR (1) TR201901462T4 (es)
WO (1) WO2014152661A1 (es)
ZA (2) ZA201505447B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202013012753U1 (de) 2012-09-12 2019-03-04 Novaliq Gmbh Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca
MX360469B (es) 2012-09-12 2018-11-05 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
PL3193867T3 (pl) * 2014-09-17 2021-07-12 Panoptica, Inc. Formulacje oczne do dostarczania leku i ochrony przedniego odcinka oka
CN120884568A (zh) 2015-09-30 2025-11-04 诺瓦利克有限责任公司 半氟化化合物和其组合物
MX2018010997A (es) 2016-03-11 2019-07-04 Georgia Pacific Gypsum Llc Paneles de yeso, sistemas y metodos.
MX388460B (es) 2017-04-21 2025-03-20 Dermaliq Therapeutics Inc Composiciones de yodo.
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
IL273531B2 (en) 2017-09-27 2024-05-01 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
AT522609B1 (de) 2019-05-28 2022-06-15 Miba Frictec Gmbh Reibvorrichtung
WO2021044045A1 (en) 2019-09-06 2021-03-11 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP4027985A1 (en) * 2019-09-13 2022-07-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Druggable target to treat retinal degeneration
WO2022235699A2 (en) 2021-05-03 2022-11-10 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
WO2025058571A1 (en) * 2023-09-15 2025-03-20 Agency For Science, Technology And Research Polymer composition comprising a thermogelling polymer and a tyrosine kinase inhibitor, and related methods thereof
WO2026002126A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其眼用制剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2201134A1 (en) 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
JPH10203960A (ja) 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
WO2001017527A1 (en) 1999-09-06 2001-03-15 Ono Pharmaceutical Co., Ltd. Preventive and therapeutic agents for eye diseases
CA2430065C (en) * 2000-11-28 2008-05-20 Pfizer Products Inc. Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
WO2004011461A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US20050007449A1 (en) * 2002-08-29 2005-01-13 Kazuyoshi Ikado Vision aid network server, vision aid network system, vision aid method, vision aid system, color sense function reporting, program for reporting color sense function, method for reporting color sense function, color sense aid system, color sense aid program, and color sense aid method
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
US7483533B2 (en) * 2004-08-05 2009-01-27 King Fahd University Of Petroleum Elliptic polynomial cryptography with multi x-coordinates embedding
JP2006111621A (ja) 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
EP1827373B1 (en) * 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
JP2008543775A (ja) * 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
JP2007012937A (ja) * 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
JP2007011785A (ja) * 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
DE602006016628D1 (de) * 2005-10-10 2010-10-14 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN103497148B (zh) * 2007-02-22 2016-06-01 科尔比制药公司 羟胺化合物及其用法
KR20100045503A (ko) * 2007-08-09 2010-05-03 센주 세이야꾸 가부시키가이샤 피레녹신 함유 2 액성 점안제
CA2729834A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
WO2010119942A1 (ja) 2009-04-17 2010-10-21 参天製薬株式会社 レボカバスチン懸濁型点眼剤
JP2012250918A (ja) 2011-05-31 2012-12-20 Rohto Pharmaceutical Co Ltd ニューキノロン剤含有水性組成物
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Also Published As

Publication number Publication date
HK1216236A1 (en) 2016-10-28
PT2968650T (pt) 2019-02-12
BR112015021334B1 (pt) 2020-04-07
RU2018128980A3 (es) 2022-01-11
CN111789814A (zh) 2020-10-20
US9446026B2 (en) 2016-09-20
IL276016A (en) 2020-08-31
CA2900840A1 (en) 2014-09-25
KR20210132205A (ko) 2021-11-03
PH12015501938B1 (en) 2019-11-13
WO2014152661A1 (en) 2014-09-25
DK2968650T3 (en) 2019-03-11
US10307404B1 (en) 2019-06-04
MX2015012653A (es) 2016-08-18
PH12015501938A1 (en) 2016-01-11
JP6542193B2 (ja) 2019-07-10
CN105142686A (zh) 2015-12-09
AU2017210543B2 (en) 2019-01-31
BR112015021334A2 (pt) 2017-07-18
CN105142686B (zh) 2020-04-10
US10092549B2 (en) 2018-10-09
ES2710152T3 (es) 2019-04-23
US20160022646A1 (en) 2016-01-28
US20190247368A1 (en) 2019-08-15
KR20150127256A (ko) 2015-11-16
US20140303219A1 (en) 2014-10-09
RU2665953C2 (ru) 2018-09-05
EP3520773A1 (en) 2019-08-07
US20190240201A1 (en) 2019-08-08
IL240510B (en) 2020-08-31
US20190183864A1 (en) 2019-06-20
ZA201505447B (en) 2022-06-29
AU2019202857B2 (en) 2021-02-18
IL276016B (en) 2022-04-01
JP2022009275A (ja) 2022-01-14
MX360888B (es) 2018-11-20
SG11201507316UA (en) 2015-10-29
RU2015143898A (ru) 2017-04-19
SG10201710928PA (en) 2018-02-27
AU2014239252B2 (en) 2017-07-06
AU2017210543A1 (en) 2017-08-17
AU2019202857A1 (en) 2019-05-16
EP2968650A1 (en) 2016-01-20
IL240510A0 (en) 2015-10-29
US20210196690A1 (en) 2021-07-01
TR201901462T4 (tr) 2019-02-21
US20240325357A1 (en) 2024-10-03
HUE042528T2 (hu) 2019-07-29
CN111789814B (zh) 2022-07-19
JP2019167377A (ja) 2019-10-03
KR102433489B1 (ko) 2022-08-17
PL2968650T3 (pl) 2019-05-31
PH12019501902A1 (en) 2021-03-01
US20160354349A1 (en) 2016-12-08
EP2968650B1 (en) 2019-01-16
CA2900840C (en) 2023-03-28
AU2014239252A1 (en) 2015-08-13
JP2016517427A (ja) 2016-06-16
SA516380321B1 (ar) 2019-01-16
ZA201907176B (en) 2022-12-21
RU2768489C2 (ru) 2022-03-24
JP6965308B2 (ja) 2021-11-10
RU2018128980A (ru) 2018-11-05

Similar Documents

Publication Publication Date Title
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MY171920A (en) Prevention and treatment of ocular conditions
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MY198195A (en) Composition For Suppressing Or Improving Eye Fatigue
IN2014CN04809A (es)
MX391659B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
TW201613596A (en) Ophthalmic suspension preparation
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
EP2962691A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT
MX2013013286A (es) Formulación y método de preparación para obtener soluciones oftálmicas derivadas de quinolonas y una enzima proteasa con propiedades antinflamatorias y analgésicas.
GR1008505B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον δορζολαμιδη και τιμολολη
GR1008509B (el) Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δορζολαμιδη